HUTCHMED (China)'s (HKG:0013) new drug application for fanregratinib (HMPL-453) was conditionally approved by China's National Medical Products Administration.
The approval is for the treatment of adult patients with advanced, metastatic or unresectable intrahepatic cholangiocarcinoma, a Friday bourse filing revealed.
Fanregratinib will be marketed in China under the brand name ATLED, the biopharmaceutical company said.
Kawan Renergy (KLSE:KENERGY) unit Magenko Renewables (Ipoh) received approval from the Sustainable Energy Development Authority Malaysia for a 2.5-megawatt biomass power plant under the 2026 Feed-in Tariff system, according to a Thursday Malaysian bourse filing.The project has an installed capacity of 2.5 megawatts, and net export capacity of 2 megawatts. The Feed-in Tariff is scheduled to commence on Aug. 17, 2029, and run for 21 years.The basic tariff is 0.38 ringgit per kilowatt-hour for the first 10 years, and 0.288 ringgit per kilowatt-hour for the remaining period.The project will be financed through IPO proceeds and bank financing, it said.
SBI Holdings (TYO:8473) plans to purchase a 20% stake in Indonesia-based online brokerage Ajaib Group for $270 million by the end of August, making the latter an equity-method affiliate, Nikkei Asia reported Friday.Ajaib offers online brokerage, foreign-exchange margin trading, cryptocurrency and asset management services. SBI Holdings plans to work with Ajaib to promote its Japanese yen stablecoin JPYSC, and expand its cryptocurrency business abroad, the report said.SBI Holdings and Ajaib Group did not immediately respond to requests for comment from.Shares of SBI Holdings added nearly 1% in recent trade.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Bank of Nanjing (SHA:601009) on Sept. 7 will fully redeem all 50 million outstanding preferred shares totaling 5 billion yuan.The move followed the receipt of a no-objection letter from the Jiangsu Regulatory Bureau, according to a Thursday aftermarket filing with the Shanghai bourse.